Alaunos Therapeutics, Inc. (TCRT)

USD 2.51

(-5.99%)

Market Cap (In USD)

4.01 Million

Revenue (In USD)

5000.00

Net Income (In USD)

-35.14 Million

Avg. Volume

495.51 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.63-33.0
PE
-0.86
EPS
-2.92
Beta Value
-0.496
ISIN
US98973P2002
CUSIP
98973P101
CIK
1107421
Shares
1601250.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Dale Curtis Hogue Jr.
Employee Count
-
Website
https://www.alaunos.com
Ipo Date
2005-08-24
Details
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.